JP2024528697A5 - - Google Patents

Info

Publication number
JP2024528697A5
JP2024528697A5 JP2024503826A JP2024503826A JP2024528697A5 JP 2024528697 A5 JP2024528697 A5 JP 2024528697A5 JP 2024503826 A JP2024503826 A JP 2024503826A JP 2024503826 A JP2024503826 A JP 2024503826A JP 2024528697 A5 JP2024528697 A5 JP 2024528697A5
Authority
JP
Japan
Prior art keywords
composition
cargo
disease
mev
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528697A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/070371 external-priority patent/WO2023001894A1/en
Publication of JP2024528697A publication Critical patent/JP2024528697A/ja
Publication of JP2024528697A5 publication Critical patent/JP2024528697A5/ja
Pending legal-status Critical Current

Links

JP2024503826A 2021-07-20 2022-07-20 微細藻類由来の細胞外小胞、その調製および使用 Pending JP2024528697A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163223828P 2021-07-20 2021-07-20
US63/223,828 2021-07-20
US202163224656P 2021-07-22 2021-07-22
US63/224,656 2021-07-22
US202263305230P 2022-01-31 2022-01-31
US63/305,230 2022-01-31
PCT/EP2022/070371 WO2023001894A1 (en) 2021-07-20 2022-07-20 Extracellular vesicles from microalgae, their preparation, and uses

Publications (2)

Publication Number Publication Date
JP2024528697A JP2024528697A (ja) 2024-07-30
JP2024528697A5 true JP2024528697A5 (enExample) 2024-09-02

Family

ID=82839059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503826A Pending JP2024528697A (ja) 2021-07-20 2022-07-20 微細藻類由来の細胞外小胞、その調製および使用

Country Status (6)

Country Link
US (1) US20240173265A1 (enExample)
EP (1) EP4373506A1 (enExample)
JP (1) JP2024528697A (enExample)
AU (1) AU2022315530A1 (enExample)
CA (1) CA3226019A1 (enExample)
WO (1) WO2023001894A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
EP4525900A1 (en) * 2022-06-14 2025-03-26 Hun-Ren Támogatott Kutatócsoportok Irodája Extracellular vesicles for use in therapy
WO2024088808A1 (en) 2022-10-24 2024-05-02 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
WO2024194423A1 (en) 2023-03-23 2024-09-26 Ags Therapeutics Sas Extracellular vesicles from microalgae, their use for vaccines and for immunomodulation
JP2024167772A (ja) * 2023-05-22 2024-12-04 マイクロアルジェコーポレーション株式会社 免疫賦活用組成物及び発現誘導用組成物
CN116836809B (zh) * 2023-09-01 2023-11-21 暨南大学 具有高虾青素含量类外泌体的基因工程微拟球藻及其应用
WO2025142932A1 (ja) * 2023-12-27 2025-07-03 ロート製薬株式会社 微細藻類由来の細胞外小胞を含有する組成物
JP7546136B1 (ja) 2023-12-27 2024-09-05 ロート製薬株式会社 微細藻類由来の細胞外小胞を含有する組成物
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
WO2025210558A1 (en) 2024-04-05 2025-10-09 Exogenus Therapeutics, Sa Compositions comprising small extracellular vesicles derived from microalgae, a process for obtaining them and uses thereof
JP7783380B1 (ja) 2024-08-27 2025-12-09 ロート製薬株式会社 細胞外小胞又は細胞外小胞含有物
CN118750522B (zh) * 2024-09-03 2024-11-01 暨南大学 虾青素类外泌体的应用
CN120000611B (zh) * 2025-01-20 2026-03-06 浙江大学医学院附属第四医院 一种靶向肝癌组织的微藻外泌体纳米颗粒及其制备方法
CN120289601A (zh) * 2025-04-17 2025-07-11 南京农业大学 小麦TaALIX蛋白在降低呕吐毒素积累和小麦抗赤霉病中的应用

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1997007788A2 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
CA2532228C (en) 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
WO2006029161A2 (en) 2004-09-07 2006-03-16 The Board Of Regents For Oklahoma State University Cell specific gene silencing using cell-specific promoters in vitro and in vivo
EP1937066A4 (en) 2005-08-18 2008-12-24 Alnylam Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES
AU2013203219B2 (en) 2005-11-02 2016-09-22 Arbutus Biopharma Corporation MODIFIED siRNA MOLECULES AND USES THEREOF
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
US20070258952A1 (en) 2006-05-04 2007-11-08 Baylor Research Institute Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA
US20080039415A1 (en) 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
CA2675954A1 (en) 2007-01-18 2008-07-24 Plant Bioscience Limited (Pbl) Methods and compositions for modulating the mirna pathway
WO2009082606A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Folate conjugates
WO2009104051A2 (en) 2007-12-31 2009-08-27 Lu Patrick Y Combinational therapeutics for treatment of prostate cancer using epoxy encapsulated magnetic particles and rnai medicine
US20110130440A1 (en) 2008-03-26 2011-06-02 Alnylam Pharmaceuticals, Inc. Non-natural ribonucleotides, and methods of use thereof
CA2721183C (en) 2008-04-11 2019-07-16 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
EP2321414B1 (en) 2008-07-25 2018-01-10 Alnylam Pharmaceuticals, Inc. Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
AU2009298802A1 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2010078517A2 (en) 2008-12-31 2010-07-08 Sirnaomics, Inc. Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer
CA3045126A1 (en) 2009-05-05 2010-11-11 Arbutus Biopharma Corporation Methods of delivering oligonucleotides to immune cells
CN102753187A (zh) 2009-06-03 2012-10-24 戴瑟纳制药公司 肽-dicer底物试剂及其特异性抑制基因表达的方法
US8957038B2 (en) 2009-07-15 2015-02-17 Medtronic, Inc. Treatment of neurological disorders
AU2010324658A1 (en) 2009-11-26 2012-05-03 Quark Pharmaceuticals, Inc. siRNA compounds comprising terminal substitutions
EP3318248B1 (en) 2009-12-01 2019-04-10 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
EP3296398A1 (en) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
WO2011072292A2 (en) 2009-12-11 2011-06-16 Dicerna Pharmaceuticals, Inc. Phase changing formulations of rna and rna derivatives
WO2011097480A1 (en) 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
WO2011133707A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013048734A1 (en) 2011-09-28 2013-04-04 Tufts Medical Center, Inc. Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes
EP2725103A3 (en) 2011-11-14 2016-01-06 Silenseed Ltd Methods and compositions for treating prostate cancer
WO2013103467A1 (en) 2012-01-06 2013-07-11 Alcon Research, Ltd. Interfering rna delivery system and uses thereof
EP2817287B1 (en) 2012-02-24 2018-10-03 Arbutus Biopharma Corporation Trialkyl cationic lipids and methods of use thereof
EA201590197A1 (ru) 2012-08-23 2015-07-30 Алиос Биофарма, Инк. Соединения для лечения парамиксовирусных вирусных инфекций
KR102396026B1 (ko) 2014-01-21 2022-05-09 안자리움 바이오사이언시스 아게 하이브리도좀, 이를 포함하는 조성물, 이의 제조 방법 및 이의 용도
WO2016057693A1 (en) 2014-10-10 2016-04-14 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
WO2016069740A1 (en) * 2014-10-29 2016-05-06 The Regents Of The University Of California Bioactive delivery vehicles
CA3017586A1 (en) * 2016-03-15 2017-09-21 Codiak Biosciences, Inc. Therapeutic membrane vesicles
GB201609216D0 (en) 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
GB2552301A (en) 2016-07-11 2018-01-24 Evox Therapeutics Ltd Metabolic drug loading of EVs
GB2552460A (en) 2016-07-11 2018-01-31 Evox Therapeutics Ltd CPP-Mediated EV Loading
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
WO2019018349A1 (en) 2017-07-17 2019-01-24 Codiak Biosciences, Inc. NANOVESICLES PRODUCED FROM MESENCHYMAL STROMAL CELLS FOR ANTI-INFLAMMATORY APPLICATIONS
IL272786B2 (en) 2017-08-25 2025-03-01 Codiak Biosciences Inc Preparation of therapeutic exosomes using membrane proteins
GB201717446D0 (en) 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
GB2568255A (en) 2017-11-08 2019-05-15 Evox Therapeutics Ltd Exosomes comprising RNA therapeutics
GB201718681D0 (en) 2017-11-13 2017-12-27 Evox Therapeutics Ltd Protein engineered extracellular vesicles
US20190175506A1 (en) 2017-11-17 2019-06-13 Codiak Biosciences, Inc. Loading of Extracellular Vesicles through Imparting of Mechanical Shear
CN111655271B (zh) 2017-12-28 2025-09-23 隆萨销售股份公司 用于免疫肿瘤学和抗炎疗法的外来体
GB201802163D0 (en) 2018-02-09 2018-03-28 Evox Therapeutics Ltd Compositions for EV storage and formulation
MX2020011570A (es) 2018-05-07 2020-11-24 Alnylam Pharmaceuticals Inc Administracion extrahepatica.
GB201809622D0 (en) 2018-06-12 2018-07-25 Evox Therapeutics Ltd Engineering extracellular vesicles for affinity purification
GB201810301D0 (en) 2018-06-22 2018-08-08 Evox Therapeutics Ltd Combinatorial gene therapy
WO2020035620A1 (en) 2018-08-17 2020-02-20 Centre National De La Recherche Scientifique (Cnrs) Rna-based therapeutic methods to protect animals against pathogenic bacteria and / or promote beneficial effects of symbiotic and commensal bacteria
EP3841112A1 (en) 2018-08-24 2021-06-30 Codiak BioSciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
KR20210105889A (ko) 2018-11-09 2021-08-27 아뷰터스 바이오파마 코포레이션 지질 나노입자 제제
CN113272426A (zh) 2018-11-16 2021-08-17 医福斯治疗有限公司 用于尿素循环蛋白和核酸的替代的细胞外囊泡
WO2020123083A1 (en) 2018-12-12 2020-06-18 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules containing a triloop
CN110699382A (zh) 2019-11-08 2020-01-17 赵凯 一种递送siRNA的外泌体的制备方法
IT201900024580A1 (it) * 2019-12-18 2021-06-18 Consiglio Nazionale Ricerche Vescicole extracellulari da microalghe
EP3967745A1 (en) * 2020-09-11 2022-03-16 Immunrise Chlorella-based production of extracellular vesicle-embedded small rnas for biocontrol applications
EP3967746A1 (en) * 2020-09-11 2022-03-16 Immunrise Chlorella-based production of extracellular vesicle-embedded small rnas for prophylactic or therapeutic applications

Similar Documents

Publication Publication Date Title
JP2024528697A5 (enExample)
JP7181880B2 (ja) 免疫療法のためのコア/シェル構造プラットホーム
JP6900054B2 (ja) Rna転写ベクター及びその使用
Akita et al. Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation
JP6792847B2 (ja) mRNAの機能化方法
US20210340550A1 (en) Nucleic acid molecules inserted expression regulation sequences, expression vector comprising nucleic acid moleclues and pharmaceutical use thereof
AU2017371665A1 (en) RNA guided eradication of human JC virus and other polyomaviruses
US20250057984A1 (en) Cell-type specific membrane fusion proteins
JP6193920B2 (ja) 生物学的又は化学的作用物質に対する予防又はそれらの治療のために遺伝子改変されたヒト臍帯血管周囲細胞
JP2007527240A5 (enExample)
US11981911B2 (en) Compositions and methods for inhibiting viral vector-induced inflammatory responses
JP6377349B2 (ja) Dna発現構築物
JP2021515037A5 (enExample)
US20210260168A1 (en) Compositions and methods of fas inhibition
CN120641465A (zh) 新颖的聚甘油缀合脂质和包含其的脂质纳米颗粒组合物
JP2025505440A5 (enExample)
JP2011525169A (ja) Toll様受容体3の選択的アゴニスト
US11944636B2 (en) Medicinal composition comprising a non-coding RNA molecule and an antibody targeting a tumor antigen
US20220153820A1 (en) Compositions and methods for treating and suppressing allergic responses
JP7642824B2 (ja) 遺伝子発現および抑制が同時に可能な核酸構造体
JP2015506696A (ja) TGF−β2発現を抑制するshRNA
CN116510022B (zh) 一种用于抗肿瘤的组合物、重组质粒组合物及其应用
CN101199862B (zh) B7-1、cd40l质粒混合物
Bogomolova et al. Genetic engineering approaches to the development of modern therapeutics
CN121825998A (zh) 编码EBV抗原蛋白的mRNA疫苗及其用途